Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline

Shieh Yueh Yang*, Huei Chun Liu, Wen Ping Chen

*此作品的通信作者

研究成果: 雜誌貢獻回顧評介論文同行評審

摘要

Although the concentrations of Alzheimer’s disease (AD) biomarkers Aβ1–40, Aβ1–42 and tau protein are very low in human plasma, ultrasensitive assays such as immunomagnetic reduction (IMR) are able to precisely quantify them. Review articles have described the detailed working mechanism of IMR and revealed the feasibility of detecting early-stage AD by assaying these plasma biomarkers with IMR. In this review, we aimed to compare the significance of these plasma biomarkers in predicting cognitive decline in patients with Down syndrome, stroke, or amnestic mild cognitive impairment based on findings in the literature. We found that plasma Aβ1–42 might play the predominant role in predicting cognitive decline in these patients.

原文英語
頁(從 - 到)435-442
頁數8
期刊Neurology and Therapy
9
發行號2
DOIs
出版狀態已發佈 - 2020 十二月 1
對外發佈

ASJC Scopus subject areas

  • 神經內科
  • 神經病學(臨床)

指紋

深入研究「Immunomagnetic Reduction Detects Plasma Aβ<sub>1–42</sub> Levels as a Potential Dominant Indicator Predicting Cognitive Decline」主題。共同形成了獨特的指紋。

引用此